Study of 23ME-01473 in Patients With Advanced Solid Malignancies
Status:
TERMINATED
Trial end date:
2024-11-10
Target enrollment:
Participant gender:
Summary
This is a first-in-human open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-01473 given by intravenous infusion in participants with advanced solid cancers who have progressed or are intolerant of available standard therapies.